Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types

Version 1 : Received: 7 January 2022 / Approved: 11 January 2022 / Online: 11 January 2022 (13:05:00 CET)

A peer-reviewed article of this Preprint also exists.

Felip, E.; Gutiérrez-Chamorro, L.; Gómez, M.; Garcia-Vidal, E.; Romeo, M.; Morán, T.; Layos, L.; Pérez-Roca, L.; Riveira-Muñoz, E.; Clotet, B.; Fernandez, P.L.; Mesía, R.; Martínez-Cardús, A.; Ballana, E.; Margelí, M. Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers 2022, 14, 641. Felip, E.; Gutiérrez-Chamorro, L.; Gómez, M.; Garcia-Vidal, E.; Romeo, M.; Morán, T.; Layos, L.; Pérez-Roca, L.; Riveira-Muñoz, E.; Clotet, B.; Fernandez, P.L.; Mesía, R.; Martínez-Cardús, A.; Ballana, E.; Margelí, M. Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers 2022, 14, 641.

Abstract

SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. However, SAMHD1 role in cancer evolution is still unknown. We performed the first in-depth study of SAMHD1 role in advanced solid tumors, by analyzing samples of 128 patients treated with chemotherapy agents based on platinum derivatives and/or antimetabolites and developing novel in vitro knock-out models to explore the mechanisms driving SAMHD1 function in cancer. Low or no expression of SAMHD1 was associated with a positive prognosis in breast, ovarian and non-small cell lung cancer (NSCLC) cancer patients. A predictive value was associated to low-SAMHD1 expression in NSCLC and ovarian patients treated with antimetabolites in combination with platinum derivatives. In vitro, SAMHD1 knock-out cells showed increased γ-H2AX and apoptosis suggesting that SAMHD1 depletion induces DNA damage leading to cell death. In vitro treatment with platinum-derived drugs significantly enhanced γ-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment. SAMHD1 expression represents a new strong prognostic and predictive biomarker in solid tumors and thus, modulation of SAMHD1 function may constitute a promising target for the improvement of cancer therapy.

Keywords

SAMHD1; NSCLC; breast cancer; ovarian cancer; solid tumors

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.